Red X iconGreen tick iconYellow tick icon
A postgraduate research opportunity at the University of Otago.


Close date
No date set
Academic background
Health Sciences
Host campus
Pathology and Biomedical Science (Christchurch)
Dr George Wiggins


Deletions overlapping the SULT1A1 gene have been shown to be associated with reduced breast cancer risk (RR=0.73, 95% CI 0.59-0.91) in BRCA1 pathogenic variant carriers. SULT1A1 function is known to be potently inhibited by ethinylestradiol (EE2), a synthetic oestrogen widely used in combined oral contraceptives.

This project aims to investigate EE2 impact whether BRCA1+/- cells treated with EE2 have reduced proliferation and reduced susceptibility to DNA damage. These will be assessed using immunocytochemistry markers, including PHH3, γ-H2AX and 53BP1 in isogenic (MCF-7BRCA1+/- and MCF-7WT) cell lines alongside SULT1A1 knockdowns.

Preferred student expertise

Science student with an interest in cancer biology and genetics, and preferably has laboratory experience.

This is one of a number of projects on offer for the 2024 intake of BBiomedSc(Hons) at the University of Otago, Christchurch campus.

Further information


Dr George Wiggins

Useful information

Similar research opportunities

Back to top